Emergent BioSolutions (EBS) Income from Continuing Operations (2011 - 2026)

Emergent BioSolutions' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 6800000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 90.0% year-over-year to 6800000.0 in Q1 2026; TTM through Mar 2026 was 8600000.0, a 93.47% increase from a year earlier, with the FY2025 full-year figure at 52600000.0, up 127.6% from the prior year.
• Income from Continuing Operations rose to 6800000.0 in Q1 2026 per EBS's latest filing, from 54600000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 114800000.0 in Q3 2024 and bottomed at 283100000.0 in Q2 2024.
• The 5-year median for Income from Continuing Operations is 49500000.0 (2023), against an average of 65052941.18.
• Across the five-year window, Income from Continuing Operations slumped 4932.43% in 2023 and soared 655.56% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 67000000.0 in 2022, then gained by 26.12% to 49500000.0 in 2023, then jumped by 36.77% to 31300000.0 in 2024, then sank by 74.44% to 54600000.0 in 2025, then soared by 112.45% to 6800000.0 in 2026.
• Per Business Quant, the three latest EBS Income from Continuing Operations figures stand at 6800000.0 (Q1 2026), 54600000.0 (Q4 2025), and 51200000.0 (Q3 2025).